CAPRISA 004 tenofovir microbicide trial: No impact of tenofovir gel on the HIV transmission bottleneck
Journal of Infectious Diseases
Institute of Infectious Diseases and Molecular Medicine, Division of Medical Virology, University of Cape Town, Anzio Rd, Observatory, 7925, South Africa; Centre for the AIDS Programme of Research in South Africa, Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa; Lineberger Comprehensive Care Center, University of North Carolina, Charlotte, United States; Department of Epidemiology, Columbia University, New York, NY, United States
Alterations of the genital mucosal barrier may influence the number of viruses transmitted from a human immunodeficiency virus-infected source host to the newly infected individual. We used heteroduplex tracking assay and single-genome sequencing to investigate the effect of a tenofovir-based microbicide gel on the transmission bottleneck in women who seroconverted during the CAPRISA 004 microbicide trial. Seventy-seven percent (17 of 22; 95 confidence interval [CI], 56-90) of women in the tenofovir gel arm were infected with a single virus compared with 92 (13 of 14; 95 CI, 67->99) in the placebo arm (P =. 37). Tenofovir gel had no discernable impact on the transmission bottleneck. © 2012 The Author.
placebo; tenofovir; amplicon; article; bottleneck population; controlled study; disease classification; gel; gene sequence; genetic distance; genetic variability; human; Human immunodeficiency virus infected patient; Human immunodeficiency virus infection; phylogeny; priority journal; seroconversion; virus transmission; Adenine; Anti-HIV Agents; Anti-Infective Agents, Local; Cervix Uteri; Cohort Studies; Female; Gels; HIV Infections; HIV-1; Humans; Mucous Membrane; Phosphonic Acids